IL1B and triple-A syndrome: Notably, no human studies have yet assessed agents such as rapamycin or anakinra dampening IL-1beta signaling, yet a review by Millar et al. [166] highlights the multifaceted and central role of IL-1beta signaling in mediating aortic wall inflammation and the progression of AAA, underscoring a translational blind spot for mechanistically promising therapies.